Welcome to LookChem.com Sign In|Join Free
  • or
(S)-6-[(S)-3-(4-Acetylamino-phenoxy)-2-hydroxy-propylamino]-heptanoic acid p-tolylamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

125452-55-3

Post Buying Request

125452-55-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

125452-55-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 125452-55-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,4,5 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 125452-55:
(8*1)+(7*2)+(6*5)+(5*4)+(4*5)+(3*2)+(2*5)+(1*5)=113
113 % 10 = 3
So 125452-55-3 is a valid CAS Registry Number.

125452-55-3Downstream Products

125452-55-3Relevant academic research and scientific papers

Synthesis and β-Adrenergic Antagonist Activity of Stereoisomeric Practolol and Propranolol Derivatives

Leftheris, Katerina,Goodman, Murray

, p. 216 - 223 (2007/10/02)

A series of stereoisomeric practolol and propranolol derivatives has been synthesized in which the N-isopropyl group of the drug was replaced by an asymmetric heptanoic acid terminated by a substituted p-toluidide of p-(tri-fluoromethyl)anilide.The asymmetric epoxide, 3-(p-acetamidophenoxy)-1,2-epoxypropane, was allowed to react with a preformed enantiomeric 6-aminoheptanoic acid amide to yield the stereoisomeric practolol congener derivatives.An asymmetric drug precursor epoxide was prepared from p-acetamidophenol and enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide).For the propranolol congener derivatives, the preformed asymmetric 6-aminoheptanoic acid amides were allowed to react with one of the enantiomers of 3-(1-naphthyloxy)-1,2-epoxypropane.This drug precursor epoxide was prepared either by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-epoxypropane (the Sharpless epoxide) or by combining 1-naphthol with enantiomeric 3-(tosyloxy)-1,2-propanediol followed by epoxidation.Pharmacological studies carried out for the practolol derivatives demonstrated a significant dependence of enhanced potency and tissue/subreceptor specificity on both the configuration of the drug asymmetric carbon and the configuration of the spacer asymmetric carbon.The compounds containing the S configuration at the drug asymmetric center and the R configuration at the spacer asymmetric carbon exhibited an increase in potency over the other stereoisomeric congener derivatives and the progenitor drug.For the propranolol congener derivatives, a large decrease in potency was observed for all of the stereoisomers over the progenitor drug.The propranolol stereoisomers containing the S configuration at the drug asymmetric center were more active than those containing the R configuration at that center.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 125452-55-3